ABCL Stock Price, AbCellera Biologics Inc Quote, Chart

Market Summary

USD3.84-0.20

Market Closed

-4.95%

ABCL Alerts

Big fall in Revenue (Y/Y)

Losses in recent quarter

ABCL Stock Price

View Fullscreen

ABCL RSI Chart

ABCL Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-7.69

Price/Sales (Trailing)

31.55

EV/EBITDA

-6.77

Price/Free Cashflow

-8.85

ABCL Price/Sales (Trailing)

ABCL Profitability

EBT Margin

-471.19%

Return on Equity

-13%

Return on Assets

-10.04%

Free Cashflow Yield

-11.3%

ABCL Fundamentals

ABCL Revenue

Revenue (TTM)

35.8M

Rev. Growth (Yr)

-37%

Rev. Growth (Qtr)

8.44%

ABCL Earnings

Earnings (TTM)

-146.9M

Earnings Growth (Yr)

-1.25%

Earnings Growth (Qtr)

13.87%

Breaking Down ABCL Revenue

Last 7 days

1.6%

Last 30 days

-14.5%

Last 90 days

-23.5%

Trailing 12 Months

-32.2%

How does ABCL drawdown profile look like?

ABCL Financial Health

Current Ratio

7.76

ABCL Investor Care

Shares Dilution (1Y)

1.84%

Diluted EPS (TTM)

-0.52

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	35.8M	0	0	0
2023	373.6M	261.7M	149.9M	38.0M
2022	489.0M	507.3M	603.2M	485.4M
2021	431.2M	447.7M	443.8M	375.2M
2020	67.0M	122.4M	177.8M	233.2M
2019	0	0	0	11.6M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of AbCellera Biologics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 26, 2024	hansen carl l. g.	acquired	151,538	2.7	56,125	chief executive officer
Dec 19, 2023	thermopylae holdings ltd.	gifted	-	-	-210,000	-
Nov 23, 2023	hansen carl l. g.	acquired	151,538	2.7	56,125	chief executive officer
Nov 08, 2023	montalbano john s.	bought	44,600	4.46	10,000	-
Nov 06, 2023	montalbano john s.	bought	92,800	4.64	20,000	-
Sep 22, 2023	hayden michael r	bought	98,200	4.91	20,000	-
Sep 12, 2023	lecault veronique	bought	103,800	5.19	20,000	chief operating officer
Aug 24, 2023	hansen carl l. g.	acquired	151,538	2.7	56,125	chief executive officer
Aug 08, 2023	hayden michael r	bought	177,000	5.9	30,000	-
May 26, 2023	thermopylae holdings ltd.	bought	997,728	6.5211	153,000	-

Which funds bought or sold ABCL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	reduced	-33.91	-912,591	1,005,920	-%
May 06, 2024	HighTower Advisors, LLC	added	7.57	-35,000	200,000	-%
May 06, 2024	Parallel Advisors, LLC	unchanged	-	-2,912	11,180	-%
May 06, 2024	DUALITY ADVISERS, LP	reduced	-38.67	-325,556	308,488	0.03%
May 03, 2024	Householder Group Estate & Retirement Specialist, LLC	sold off	-100	-2,000	-	-%
May 03, 2024	Intellectus Partners, LLC	reduced	-38.94	-2,612,110	2,454,280	0.64%
May 03, 2024	AA Financial Advisors, LLC	unchanged	-	-11,800	45,300	0.02%
May 03, 2024	SIGNATUREFD, LLC	added	4.91	-10,148	50,355	-%
May 03, 2024	GSA CAPITAL PARTNERS LLP	reduced	-75.44	-1,612,000	390,000	0.03%
May 02, 2024	Integrity Financial Corp /WA	unchanged	-	-14,219	54,587	0.04%

Are Funds Buying or Selling ABCL?

Are funds buying ABCL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ABCL

No. of Funds

Unveiling AbCellera Biologics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	baker bros. advisors lp	7.9%	22,909,753	SC 13G
Feb 13, 2024	hansen carl l. g.	20.6%	60,740,524	SC 13G/A
Jan 29, 2024	baillie gifford & co	8.29%	24,044,796	SC 13G/A
Apr 24, 2023	thiel peter	4.99%	14,360,427	SC 13D/A
Feb 13, 2023	capital world investors	3.3%	9,327,493	SC 13G/A
Feb 06, 2023	hansen carl l. g.	20.4%	58,993,307	SC 13G/A
Jan 18, 2023	baillie gifford & co	6.88%	19,696,735	SC 13G
Feb 14, 2022	dcvc bio, l.p.	2.6%	7,305,761	SC 13G/A
Feb 14, 2022	viking global investors lp	0.0%	0	SC 13G/A
Feb 11, 2022	capital world investors	7.8%	22,051,703	SC 13G

Recent SEC filings of AbCellera Biologics Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	8-K	Current Report
May 07, 2024	10-Q	Quarterly Report
Apr 29, 2024	DEFA14A	DEFA14A
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	ARS	ARS
Feb 27, 2024	4	Insider Trading
Feb 23, 2024	8-K	Current Report
Feb 20, 2024	S-8	Employee Benefits Plan
Feb 20, 2024	8-K	Current Report
Feb 20, 2024	10-K	Annual Report

Peers (Alternatives to AbCellera Biologics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.7B	6.8B	16.03%	-8.84%	-7.83	6.82	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	-2.41%	-26.73%	-58.01	9.62	75.20%	68.82%
BMRN	15.5B	2.5B	-6.28%	-14.44%	75.6	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-2.82%	-17.40%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.2B	107.9M	-2.02%	101.31%	-9.48	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-21.41%	-52.73%	-12.3	9.79	394.93%	39.61%
AXSM	3.6B	251.0M	5.14%	-1.20%	-12.15	14.35	73.58%	-86.73%
ARWR	3.1B	240.7M	-1.87%	-37.68%	-10.53	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-3.99%	-20.25%	-45.95	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-5.16%	-15.46%	24.28	4.35	85.90%	-14.05%
NVAX	625.6M	983.7M	0.90%	-53.05%	-1.15	0.64	-50.36%	17.16%
CRBP	451.6M	881.7K	5.23%	376.44%	-13.38	481.06	-77.61%	33.36%
INO	257.1M	4.9M	-3.00%	9.13%	-1.9	52.83	-54.97%	51.71%
IBIO	6.6M	2.1M	-15.93%	74.31%	-0.24	2.14	-13.45%	66.37%

AbCellera Biologics Inc News

Latest updates

AbCellera Biologics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	8.4%	10.00	9.00	7.00	10.00	16.00	22.00	101	46.00	317	139	5.00	28.00	203	208	9.00	11.00	5.00	-
Operating Expenses	-13.8%	65.00	75.00	61.00	61.00	77.00	59.00	64.00	54.00	92.00	58.00	34.00	35.00	45.00	47.00	11.00	12.00	7.00	-
S&GA Expenses	8.5%	3.00	3.00	3.00	4.00	4.00	3.00	3.00	3.00	2.00	2.00	1.00	1.00	3.00	2.00	1.00	1.00	0.00	-
R&D Expenses	-19.2%	39.00	49.00	38.00	36.00	53.00	28.00	27.00	27.00	26.00	17.00	17.00	15.00	12.00	9.00	7.00	9.00	4.00	-
EBITDA Margin	-2.9%	-4.05*	-3.94*	-0.84*	-0.16*	-0.03*	0.55*	0.62*	0.59*	0.62*	0.62*	0.68*	0.72*	-	-	-	-	-	-
Income Taxes	-47.2%	-2.14	-1.45	-10.67	-7.48	-8.04	-1.52	20.00	-0.10	62.00	25.00	-3.59	0.00	44.00	-	-	-	-	-
Earnings Before Taxes	12.0%	-42.75	-48.60	-39.28	-38.00	-48.15	-31.41	47.00	-6.89	231	85.00	-24.97	-2.07	161	156	-2.69	7.00	-2.09	-
EBT Margin	-3.0%	-4.71*	-4.58*	-1.05*	-0.27*	-0.11*	0.49*	0.59*	0.56*	0.59*	0.58*	0.65*	0.70*	-	-	-	-	-	-
Net Income	13.9%	-40.61	-47.15	-28.61	-30.53	-40.11	-29.89	27.00	-6.78	169	60.00	-21.38	-2.32	117	2.00	-2.69	7.00	-2.09	-
Net Income Margin	-6.6%	-4.10*	-3.85*	-0.86*	-0.28*	-0.13*	0.33*	0.41*	0.39*	0.42*	0.41*	0.21*	0.25*	-	-	-	-	-	-
Free Cashflow	-93.4%	-65.85	-34.04	-20.44	-7.30	-59.05	19.00	-139	242	86.00	-26.14	-14.51	121	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-1.7%	1,463	1,488	1,512	1,537	1,498	1,541	1,552	1,594	1,592	1,319	1,173	1,152	1,129	1,006
Current Assets	-6.7%	814	872	920	931	941	1,025	1,046	1,144	1,174	930	804	864	908	813
Cash Equivalents	11.4%	149	133	172	180	193	387	397	816	571	501	518	793	686	594
Net PPE	-	-	-	277	260	233	217	201	149	122	112	92.00	87.00	35.00	18.00
Goodwill	0.0%	48.00	48.00	48.00	48.00	48.00	48.00	48.00	48.00	48.00	48.00	49.00	32.00	32.00	32.00
Liabilities	-0.8%	333	336	329	342	289	308	302	381	385	293	219	184	171	175
Current Liabilities	-11.9%	105	119	110	119	90.00	118	106	221	213	121	50.00	70.00	88.00	103
Shareholder's Equity	-1.9%	1,130	1,152	1,183	1,195	1,209	1,233	1,250	1,213	1,208	1,026	953	968	957	831
Retained Earnings	-14.5%	239	280	327	356	386	426	456	429	436	268	208	229	231	114
Additional Paid-In Capital	5.7%	128	121	109	96.00	82.00	74.00	64.00	56.00	45.00	35.00	27.00	22.00	15.00	6.00
Shares Outstanding	0%	291	291	287	287	287	287	285	284	284	276	279	272	-	-
Float	-	-	-	-	1,464	-	-	-	2,404,552	-	-	-	3,794,989	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	-112.7%	-41,708	-19,611	-106	19,903	-44,063	30,912	-126,786	273,015	100,219	-16,712	-5,932	157,683	109,545	1,278	-3,801	25,977	-764	-
Share Based Compensation	5.8%	17,409	16,448	15,862	16,399	15,474	13,323	11,754	12,113	12,291	9,038	7,708	8,473	5,427	4,622	1,932	606	1,237	-
Cashflow From Investing	223.0%	29,910	-24,323	-12,786	-34,390	-149,609	-17,063	-281,994	-27,197	-26,371	-1,149	-269,626	-45,633	-15,839	-108,182	-3,885	-2,130	-5,583	-
Cashflow From Financing	-24.8%	2,831	3,765	6,630	419	-458	349	-19.00	1,173	-3,131	1,834	898	-5,075	-1,543	609,939	-14,370	346	87,738	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ABCL Income Statement

2024-03-31

Condensed Consolidated Statements of Loss and Comprehensive Loss - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Revenue:

Total revenue

$ 9,954

$ 12,192

Operating expenses:

Research and development

^[1]

39,287

52,647

Sales and marketing

^[1]

3,365

3,771

General and administrative

^[1]

17,352

15,134

Depreciation and amortization

4,844

5,514

Total operating expenses

64,848

77,066

Loss from operations

(54,894)

(64,874)

Other (income) expense

Interest income

(10,401)

(9,759)

Grants and incentives

(3,275)

(3,374)

Other

1,529

(3,593)

Total other (income)

(12,147)

(16,726)

Net loss before income tax

(42,747)

(48,148)

Income tax recovery

(2,137)

(8,038)

Net loss

(40,610)

(40,110)

Foreign currency translation adjustment

(96)

(630)

Comprehensive loss

$ (40,706)

$ (40,740)

Net loss per share

Basic (USD per share)

$ (0.14)

Diluted (USD per share)

$ (0.14)

Weighted-average common shares outstanding

Basic (in shares)

292,723,901

287,767,136

Diluted (in shares)

292,723,901

287,767,136

Research fees

Revenue:

Total revenue

$ 9,774

$ 10,570

Licensing revenue

Revenue:

Total revenue

180

372

Milestone payments

Revenue:

Total revenue

$ 0

$ 1,250

[1]	Exclusive of depreciation and amortization

ABCL Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 123,572	$ 133,320
Marketable securities	574,451	627,265
Total cash, cash equivalents, and marketable securities	698,023	760,585
Accounts and accrued receivable	34,419	30,590
Restricted cash	25,000	25,000
Other current assets	56,506	55,810
Total current assets	813,948	871,985
Long-term assets:
Property and equipment, net	306,081	287,696
Intangible assets, net	118,736	120,425
Goodwill	47,806	47,806
Investments in equity accounted investees	71,592	65,938
Other long-term assets	104,933	94,244
Total long-term assets	649,148	616,109
Total assets	1,463,096	1,488,094
Current liabilities:
Accounts payable and other current liabilities	42,887	49,580
Contingent consideration payable	51,431	50,475
Deferred revenue	10,565	18,958
Total current liabilities	104,883	119,013
Long-term liabilities:
Operating lease liability	68,079	71,222
Deferred revenue	8,570	8,195
Deferred government contributions	110,579	95,915
Contingent consideration payable	5,063	4,913
Deferred tax liability	30,274	30,612
Other long-term liabilities	5,735	5,906
Total long-term liabilities	228,300	216,763
Total liabilities	333,183	335,776
Commitments and contingencies
Shareholders' equity:
Common shares: no par value, unlimited authorized shares at December 31, 2023 and March 31, 2024: 290,824,970 and 293,621,312 shares issued and outstanding at December 31, 2023 and March 31, 2024, respectively	764,562	753,199
Additional paid-in capital	127,990	121,052
Accumulated other comprehensive loss	(1,816)	(1,720)
Accumulated earnings	239,177	279,787
Total shareholders' equity	1,129,913	1,152,318
Total liabilities and shareholders' equity	$ 1,463,096	$ 1,488,094

About AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

CEO	Dr. Carl L.G. Hansen Ph.D.
WEBSITE	abcellera.com
INDUSTRY	Biotechnology
EMPLOYEES	590

AbCellera Biologics Inc Frequently Asked Questions

What is the ticker symbol for AbCellera Biologics Inc? What does ABCL stand for in stocks?

ABCL is the stock ticker symbol of AbCellera Biologics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AbCellera Biologics Inc (ABCL)?

As of Wed May 08 2024, market cap of AbCellera Biologics Inc is 1.13 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABCL stock?

You can check ABCL's fair value in chart for subscribers.

What is the fair value of ABCL stock?

You can check ABCL's fair value in chart for subscribers. The fair value of AbCellera Biologics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AbCellera Biologics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABCL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AbCellera Biologics Inc a good stock to buy?

The fair value guage provides a quick view whether ABCL is over valued or under valued. Whether AbCellera Biologics Inc is cheap or expensive depends on the assumptions which impact AbCellera Biologics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABCL.

What is AbCellera Biologics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, ABCL's PE ratio (Price to Earnings) is -7.69 and Price to Sales (PS) ratio is 31.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABCL PE ratio will change depending on the future growth rate expectations of investors.